HP Donates BioPrinters to Help Combat Covid‐19
HP have been working tirelessly throughout the Covid-19 pandemic to research and develop technologies and innovations to help find a cure for the virus.
By donating their D300e BioPrinters to organisations within the drug and vaccine industry, they hope in turn, the use of the latest technology will contribute towards extensive research into combatting the Covid-19 global pandemic.
We are extremely proud to be part of the HP family as together we unite in the battle against Covid-19. Our parent company HP Inc. is the world leader in fluidic based Micro Electro-Mechanical Systems (MEMS) devices embodied in inkjet printing today.
HP has invested billions of dollars in research and development, as well as capital equipment over the past three decades to create the world’s largest digital printing company. All this provides the foundation to extend this technology into new domains.
HP’s expert teams have collaborated to bring HP’s first life science application in this space to market: The HP D300e BioPrinter with inkjet printing technology is enabling automated laboratory dispensing to “print” pharmaceutical samples instead of ink, which is what the devices were primarily designed for.
The BioPrinter is being used by labs and pharmaceutical companies all over the world, including the Centers for Disease Control & Prevention (CDC) in the Antibiotic Resistance (AR) Lab Network, to perform antimicrobial susceptibility testing for health departments and hospitals nationwide.
We are looking forward to seeing the developments within drug and vaccine research through the work of the BioPrinters supplied by HP Inc.